Pharmaceutical Research

, Volume 18, Issue 8, pp 1185–1189 | Cite as

Effects of Food on the Pharmacokinetics of Methylphenidate

  • K. K. Midha
  • G. McKay
  • M. J. Rawson
  • E. D. Korchinski
  • J. W. Hubbard


Purpose. To test the hypothesis that the pharmacokinetics of d-meth- ylphenidate (d-MPH) would be altered by food ingested before administration of an immediate release formulation (dl-MPH- IR) but not when food is ingested before a slow release formulation (dl-MPH-SR).

Methods. A randomized, four-phase, open label, crossover design was conducted in 24 healthy men who each received, on separate occasions, dl-MPH-IR and dl-MPH-SR taken after an overnight fast and 15 min after a standardized breakfast (20% protein, 21% fat, 59% carbohydrate). Plasma MPH levels were monitored by a validated, stereoselective, GLC-ECD method.

Results. For plasma d-MPH, there were significant differences (ANOVA) between dl-MPH-IR and dl-MPH-SR in tmax, Cmax (peak exposure), and Cmax/AUC (sensitive to rate of absorption). Dl-MPH-SR on average delayed tmax from 2.3 to 3.7 h and lowered Cmax 34%. There was no significant difference between the formulations in AUC (extent of absorption). For dl-MPH-IR, food significantly increased Cmax (23%) and AUC (15%) and for dl-MPH-SR the corresponding increases were Cmax (17%) and AUC (14%). After dl-MPH-IR, food delayed average tmax from 2.0 to 2.5 but had no effect on tmax after dl-MPH-SR. There was no effect of food on Cmax/AUC (rate of absorption).

Conclusions. Food caused a significant increase in extent of absorption but had no effect on rate of absorption of d-MPH after either dl-MPHIR or dl-MPH-SR.

d-methylphenidate immediate release slow release pharmacokinetics food effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    N. Srinivas, J. Hubbard, E. Korchinski, and K. Midha. Stereoselective urinary pharmacokinetics of dl-threo-methylphenidate and its major metabolite in humans. J. Pharm. Sci. 81:747-749 (1992).Google Scholar
  2. 2.
    N. Srinivas, J. Hubbard, E. Korchinski, and K. Midha. Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm. Res. 10:14-21 (1993).Google Scholar
  3. 3.
    T. Aoyoma, H. Kotaki, Y. Honda, and F. Nakagawa. Kinetic-analysis of enantiomers of threo-methylphenidate and its metabolite after oral administration as determined by a gas chromatographic-mass spectrometric method. J. Pharm. Sci. 79:465-469 (1990).Google Scholar
  4. 4.
    N. Srinivas, J. Hubbard, D. Quinn, and K. Midha. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin. Pharmacol. Ther. 52:561-568 (1992).Google Scholar
  5. 5.
    B. Faraj, Z. Istraili, J. Perel, M. Jenkins, S. Holtzman, S. Cucinell, and P. Dayton. Metabolism and disposition of methylphenidate-14C: studies in man and animals. J. Pharmacol. Exp. Ther. 191:535-547 (1974).Google Scholar
  6. 6.
    C. L. DeVane, J. S. Markowitz, S. W. Carson, D. W. Boulton, H. S. Gill, Z. Nahas, and S. C. Risch. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. J. Clin. Psychopharmacol. 20:347-349 (2000).Google Scholar
  7. 7.
    R. Yoss and D. Daly. On the treatment of narcolepsy. Med. Clin. North Am. 52:781-787 (1968).Google Scholar
  8. 8.
    L. Oettinger and L. Majovshi. Methylphenidate: A review. South. Med. J. 69:161-163 (1976).Google Scholar
  9. 9.
    Y.-P. Chan, J. Swanson, S. Soldin, J. Theissen, S. Macleod, and W. Logan. Methylphenidate hydrochloride given with or before breakfast. II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics 72:56-59 (1983).Google Scholar
  10. 10.
    C. Gualtieri, W. Wargin, R. Kanoy, W. Youngblood, and G. Breese. The effects of fasting and eating on the absorption of methylphenidate. Res. Commun. Psychol. Psychiatry Behav. 7:381-384 (1982).Google Scholar
  11. 11.
    K. Patrick, A. Straughn, E. Jarvi, G. Breese, and M. Meyer. The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. Biopharm. Drug Dispos. 10:165-171 (1989).Google Scholar
  12. 12.
    N. B. Modi, B. Wang, W. T. Hu, and S. K. Gupta. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm. Drug Dispos. 21:23-31 (2000).Google Scholar
  13. 13.
    N. Srinivas, D. Quinn, J. Hubbard, and K. Midha. Stereoselective disposition of methylphenidate in children with attention deficit disorder. J. Pharmacol. Exp. Ther. 241:300-306 (1987).Google Scholar
  14. 14.
    B. Singh. Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet. 37:213-255 (1999).Google Scholar
  15. 15.
    M. Modi, J. Hassett, and D. Lalka. Influence of posture on hepatic perfusion and the presystemic biotransformation of propranolol: simulation of the food effect. Clin. Pharmacol. Ther. 44:268-274 (1988).Google Scholar
  16. 16.
    H. Semple and F. Xia. Interaction between propranolol and amino acids in the single-pass isolated, perfused rat liver. Drug Metab. Dispos. 23:794-798 (1995).Google Scholar
  17. 17.
    H. Leidholm and A. Melander. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin. Pharmacol. Ther. 40:29-36 (1986).Google Scholar
  18. 18.
    T. Walle, T. Fagan, U. Walle, M. Oexmann, E. Conradi, and T. Gaffney. Food induced increase in propranolol bioavailability: relationship to protein and effects on metabolites. Clin. Pharmacol. Ther. 30:790-795 (1981).Google Scholar
  19. 19.
    C. Svensson, P. Mauriello, S. Barde, E. Middleton, and D. Lalka. Effect of carbohydrate on estimated hepatic blood flow. Clin. Pharmacol. Ther. 35:660-665 (1984).Google Scholar
  20. 20.
    J. Power, D. Morgan, and A. McLean. Effect of sensory (teasing) exposure to food on oral propranolol bioavailability. Biopharm. Drug Dispos. 16:579-589 (1995).Google Scholar
  21. 21.
    L. Endrenyi, S. Fritsch, and W. Yan. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int. J. Clin. Pharmacol. Ther. Toxicol. 29:394-399 (1991).Google Scholar
  22. 22.
    L. Endrenyi and W. Yan. Variation of Cmax and Cmax/AUC in investigations of bioequivalence. Int. J. Clin. Pharmacol. Ther. Toxicol. 31:184-189 (1993).Google Scholar
  23. 23.
    R. Rosse and W. Licamele. Slow release methylphenidate: problems when children chew tablets. J. Clin. Psychiatry 48:525.Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • K. K. Midha
    • 1
    • 2
    • 3
  • G. McKay
    • 1
  • M. J. Rawson
    • 1
  • E. D. Korchinski
    • 2
  • J. W. Hubbard
    • 1
    • 3
  1. 1.PharmaLytics Inc.SaskatoonCanada
  2. 2.College of MedicineUniversity of SaskatchewanSaskatoonCanada
  3. 3.College of Pharmacy and NutritionUniversity of SaskatchewanSaskatoonCanada

Personalised recommendations